ITCI vs. VIE, RARX, AIMT, KURA, IRWD, GMAB, TEVA, ALNY, RPRX, and BMRN
Should you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include Viela Bio (VIE), Ra Pharmaceuticals (RARX), Aimmune Therapeutics (AIMT), Kura Oncology (KURA), Ironwood Pharmaceuticals (IRWD), Genmab A/S (GMAB), Teva Pharmaceutical Industries (TEVA), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN).
Viela Bio (NASDAQ:VIE) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
In the previous week, Intra-Cellular Therapies had 3 more articles in the media than Viela Bio. MarketBeat recorded 3 mentions for Intra-Cellular Therapies and 0 mentions for Viela Bio. Viela Bio's average media sentiment score of 1.36 beat Intra-Cellular Therapies' score of 0.00 indicating that Intra-Cellular Therapies is being referred to more favorably in the news media.
47.0% of Viela Bio shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 31.5% of Viela Bio shares are held by company insiders. Comparatively, 3.4% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Viela Bio has a net margin of 0.00% compared to Viela Bio's net margin of -21.57%. Viela Bio's return on equity of -18.49% beat Intra-Cellular Therapies' return on equity.
Viela Bio has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.
Intra-Cellular Therapies has a consensus price target of $92.73, indicating a potential upside of 35.55%. Given Viela Bio's higher possible upside, analysts clearly believe Intra-Cellular Therapies is more favorable than Viela Bio.
Viela Bio has higher earnings, but lower revenue than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Viela Bio, indicating that it is currently the more affordable of the two stocks.
Intra-Cellular Therapies received 502 more outperform votes than Viela Bio when rated by MarketBeat users. Likewise, 67.38% of users gave Intra-Cellular Therapies an outperform vote while only 40.00% of users gave Viela Bio an outperform vote.
Summary
Intra-Cellular Therapies beats Viela Bio on 12 of the 17 factors compared between the two stocks.
Get Intra-Cellular Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intra-Cellular Therapies Competitors List
Related Companies and Tools
